effect inhibitor leukotrien gener airway respons allergen challeng asthmat patient effect singl oral dose mg zileuton specif inhibitor earli late airway respons allergen randomis doubl blind placebo trial subject atop asthma leukotrien gener vivo urinari leukotrien LT excret vivo calcium whole blood product zileuton inhibit ex vivo product reduc urinari excret half trend earli asthmat respons day zileuton treatment statist signific zileuton reduct maximum fall earli asthmat respons reduct urinari excret reduct gener ex vivo signific chang allergen late asthmat respons increas airway respons antigen result support hypothesi cysteinyl leukotrien role allergen earli asthmat respons complet vivo inhibit signific reduct airway respons challeng 